A partnership dispute over co-promotion duties between LG Life Sciences and Sanofi-Aventis Korea, the local affiliate of France's Sanofi, threatens to spill over into the courts if the two companies cannot settle their differences.
Osaka-based Takeda Pharmaceutical has lined up another gastrointestinal deal, this time to work with Montreal-based enGene to develop new treatments.
Partners GlaxoSmithKline and Five Prime Therapeutics are abandoning their hopes of developing an early-stage drug for lung cancer, pivoting to mesothelioma as the landscape gets more and more competitive.
In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna Therapeutics widened their R&D operations, while some smaller players signed deals and roped in cash to keep their projects moving.
Less than a year after Sanofi downsized its cancer drug R&D operations, the pharma giant has struck back-to-back deals to launch new immuno-oncology drug programs, looking to continue to beef up in a field where the company has fallen far behind its top rivals.
Fledgling Cambridge, MA-based startup Surface Oncology has pulled off its first Big Pharma deal, grabbing $170 million in near-term milestones, an upfront and research support from Novartis as it pursues next-gen cancer immuno-therapies.
Three years after Sanofi signed on to back Cambridge, MA-based Warp Drive Bio, taking an option to buy, the pharma giant has stepped back up to retool the terms, opting for a 5-year collaboration potentially worth $750 million while leaving the biotech free to pursue its own independent future.
Moderna Therapeutics, a high-profile private biotech with scores of preclinical projects, is finally moving toward human trials, recruiting one of the world's largest CROs to help get its much-hyped pipeline moving.
The R&D collaboration efforts keeping coming from Osaka-based Takeda Pharmaceutical with a push now on Parkinson's disease with NsGene looking at a regenerative therapy involving a biotherapeutic brain implant.
Pharma giant Johnson & Johnson said it has licensed the rights to various liver treatments from a unit of Hong Kong-based Sino Biopharmaceutical that it hopes will help lead to a cure for chronic hepatitis B.